Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (not Quoin Pharmaceuticals) on August 7, 2018, covering the month of August 2018. The registrant is a foreign private issuer based in Kfar Saba, Israel, focused on stem cell selection technology.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose a corporate event via an attached press release and does not contain financial statements.
Material Changes
The primary material event disclosed is the granting of a key European patent for the company's stem cell selection technology, as detailed in the attached press release (Exhibit 99.1).
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward Looking Statements" from the attached press release. No specific numerical guidance, management commentary on financial performance, or detailed risk factors are provided within the text of this Form 6-K itself.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) to understand the scope and implications of the granted European patent.
- Confirm the specific patent number and jurisdiction details referenced in the press release.
- Review the incorporated "Forward Looking Statements" for any assumptions regarding commercialization timelines.
- Check subsequent filings for financial impact or milestones related to this patent grant.